| Akolea K Santos, MD | |
|
401 Kamokila Blvd, Kapolei, HI 96707-5607 | |
| (808) 432-3600 | |
| Not Available |
| Full Name | Akolea K Santos |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 401 Kamokila Blvd, Kapolei, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285048751 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0116026878 (Virginia) | Secondary |
| 207Q00000X | Family Medicine | MD-19019 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital | Honolulu, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hawaii Permanente Medical Group Inc | 7618880667 | 541 |
News Archive
Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Genetics may play a surprisingly small role in determining the precise wiring of the mammalian nervous system, according to painstaking mapping of every neuron projecting to a small muscle mice use to move their ears.
Women and men appear to respond differently to the same biochemical manipulation.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
› Verified 2 days ago
| Entity Name | Hawaii Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710945969 PECOS PAC ID: 7618880667 Enrollment ID: O20031106000625 |
News Archive
Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Genetics may play a surprisingly small role in determining the precise wiring of the mammalian nervous system, according to painstaking mapping of every neuron projecting to a small muscle mice use to move their ears.
Women and men appear to respond differently to the same biochemical manipulation.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
› Verified 2 days ago
| Entity Name | Straub Clinic & Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457306508 PECOS PAC ID: 6305759754 Enrollment ID: O20031111000417 |
News Archive
Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Genetics may play a surprisingly small role in determining the precise wiring of the mammalian nervous system, according to painstaking mapping of every neuron projecting to a small muscle mice use to move their ears.
Women and men appear to respond differently to the same biochemical manipulation.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Akolea K Santos, MD 401 Kamokila Blvd, Kapolei, HI 96707-5607 Ph: (808) 432-3600 | Akolea K Santos, MD 401 Kamokila Blvd, Kapolei, HI 96707-5607 Ph: (808) 432-3600 |
News Archive
Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led by Venrock and Aisling Capital. Existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participated in the round.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.
Genetics may play a surprisingly small role in determining the precise wiring of the mammalian nervous system, according to painstaking mapping of every neuron projecting to a small muscle mice use to move their ears.
Women and men appear to respond differently to the same biochemical manipulation.
GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
› Verified 2 days ago
Dr. James R Best, MD, MPH Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 599 Farrington Hwy, Kapolei, HI 96707 Phone: 808-432-3600 | |
Emily N. Sumner, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Blvd, Kapolei, HI 96707 Phone: 808-432-3600 | |
Janette M. Brunken, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Blvd, Kapolei, HI 96707 Phone: 808-432-3600 | |
Ashley Kong Brimley, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 599 Farrington Hwy Ste 100, Kapolei, HI 96707 Phone: 808-697-3800 Fax: 808-674-9741 | |
Elsa K. Tsutaoka, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Blvd, Kapolei, HI 96707 Phone: 808-432-3600 | |
Jessica A. Ono, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Blvd, Kapolei, HI 96707 Phone: 808-432-3600 |